Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Evaluation of Osteogenesis and Angiogenesis of Icariin in Local Controlled Release and Systemic Delivery for Calvarial Defect in Ovariectomized Rats.

Wu Y, Cao L, Xia L, Wu Q, Wang J, Wang X, Xu L, Zhou Y, Xu Y, Jiang X.

Sci Rep. 2017 Jul 11;7(1):5077. doi: 10.1038/s41598-017-05392-z.

2.

Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Drake MT, Clarke BL, Oursler MJ, Khosla S.

Endocr Rev. 2017 Aug 1;38(4):325-350. doi: 10.1210/er.2015-1114. Review.

PMID:
28651365
3.

Can denosumab be a substitute, competitor, or complement to bisphosphonates?

Kim SY, Ok HG, Birkenmaier C, Kim KH.

Korean J Pain. 2017 Apr;30(2):86-92. doi: 10.3344/kjp.2017.30.2.86. Epub 2017 Mar 31. Review.

4.

Bisphosphonates and atypical subtrochanteric fractures of the femur.

Kharwadkar N, Mayne B, Lawrence JE, Khanduja V.

Bone Joint Res. 2017 Mar;6(3):144-153. doi: 10.1302/2046-3758.63.BJR-2016-0125.R1.

5.

Increased Bone Mass in Female Mice Lacking Mast Cell Chymase.

Lind T, Gustafson AM, Calounova G, Hu L, Rasmusson A, Jonsson KB, Wernersson S, Ã…brink M, Andersson G, Larsson S, Melhus H, Pejler G.

PLoS One. 2016 Dec 9;11(12):e0167964. doi: 10.1371/journal.pone.0167964. eCollection 2016.

6.

Intravenous zoledronate for osteoporosis: less might be more.

Grey A.

Ther Adv Musculoskelet Dis. 2016 Aug;8(4):119-23. doi: 10.1177/1759720X16650866. Epub 2016 May 19. Review.

7.

Aryl hydrocarbon receptors in osteoclast lineage cells are a negative regulator of bone mass.

Yu TY, Pang WJ, Yang GS.

PLoS One. 2015 Jan 23;10(1):e0117112. doi: 10.1371/journal.pone.0117112. eCollection 2015.

8.

Bone loss and fractures in limbs paralyzed by spinal cord injury: Prevention, diagnosis, and treatment.

Ragnarsson KT.

J Spinal Cord Med. 2015 Jan;38(1):10-2. doi: 10.1179/2045772314Y.0000000200. Epub 2014 Aug 17. No abstract available.

9.

Strawberry notch homologue 2 regulates osteoclast fusion by enhancing the expression of DC-STAMP.

Maruyama K, Uematsu S, Kondo T, Takeuchi O, Martino MM, Kawasaki T, Akira S.

J Exp Med. 2013 Sep 23;210(10):1947-60. doi: 10.1084/jem.20130512. Epub 2013 Aug 26.

10.

Pharmacogenomics of endocrine therapy in breast cancer.

Ingle JN.

J Hum Genet. 2013 Jun;58(6):306-12. doi: 10.1038/jhg.2013.35. Epub 2013 May 2. Review.

11.

Nuclear receptors in bone physiology and diseases.

Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, Kato S.

Physiol Rev. 2013 Apr;93(2):481-523. doi: 10.1152/physrev.00008.2012. Review.

12.

Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.

Cavalli L, Brandi ML.

Ther Clin Risk Manag. 2012;8:253-66. doi: 10.2147/TCRM.S7688. Epub 2012 Jun 11.

13.

Is nitroglycerin a novel and inexpensive treatment for osteoporosis?

Khosla S.

JAMA. 2011 Feb 23;305(8):826-7. doi: 10.1001/jama.2011.191. No abstract available.

14.

Update on estrogens and the skeleton.

Khosla S.

J Clin Endocrinol Metab. 2010 Aug;95(8):3569-77. doi: 10.1210/jc.2010-0856. Review.

15.

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.

Pazianas M, Cooper C, Ebetino FH, Russell RG.

Ther Clin Risk Manag. 2010 Jul 21;6:325-43.

16.

Measuring and improving adherence to osteoporosis pharmacotherapy.

Cadarette SM, Burden AM.

Curr Opin Rheumatol. 2010 Jul;22(4):397-403. doi: 10.1097/BOR.0b013e32833ac7fe. Review.

17.

New treatment modalities in osteoporosis.

Canalis E.

Endocr Pract. 2010 Sep-Oct;16(5):855-63. doi: 10.4158/EP10048.RA. Review.

18.

Approaches to treating osteoporosis.

Kent A.

Rev Obstet Gynecol. 2009 Fall;2(4):247. No abstract available.

Supplemental Content

Support Center